Management Team – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Fri, 15 Oct 2021 19:05:27 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 Glow LifeTech Strengthens Management Team with Manufacturing and Product Development Leaders; Provides Management Overview https://mjshareholders.com/glow-lifetech-strengthens-management-team-with-manufacturing-and-product-development-leaders-provides-management-overview/ Fri, 15 Oct 2021 19:05:27 +0000 https://www.cannabisfn.com/?p=2935573

Ryan Allway

October 15th, 2021


Toronto, Ontario–(Newsfile Corp. – October 14, 2021) – Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) (“Glow” or the “Company“) is pleased to provide an update on new appointments to support the Company’s advancing manufacturing and commercial initiatives including the appointment of Josh Bald, CPA as Glow’s dedicated CFO.

As with many industries, Glow’s setup of manufacturing and production related operations have been delayed due to supply shortages stemming from the COVID-19 pandemic. The Company now anticipates that these delays are coming to an end and in turn has accelerated the expansion of its product development and manufacturing team with the appointment of Brian Dymond as Director of Manufacturing and Petro Czupiel, Ph.D as Lead Product Development Scientist.

“We are thrilled to welcome Petro and Brian to the team, and confident in their leadership and contributions to the advancement of our disruptive product lines,” said W. Clark Kent, CEO of Glow LifeTech Corp.

Petro Czupiel, Ph.D
Lead Product Development Scientist

Petro obtained his Ph.D from University of Toronto at the Department of Chemical Engineering in collaboration with the Institute of Biomaterials and Biomedical Engineering. Petro has worked on and published scientific articles related to various microemulsion and nanoemulsion components and systems during his graduate studies. Petro has a breadth of formulation science experience, developing nanoemulsions of nutraceuticals and nutrient compounds. He was formerly a formulation scientist at a top 5 Canadian cannabis extraction company and advanced product formulations from concept to product, including stability programs, taste, testing, validation, and scale-up of production processes. Petro led the design of rapid-acting cannabis beverages, water-soluble cannabis extracts, advanced edibles, and topical creams. He was formerly the Chief Science Officer at Next Remedies located in Toronto. Petro’s experience and expertise in formulation will be of tremendous value to executing Glow’s product development strategy.

Brian Dymond
Director of Manufacturing

Mr. Dymond has over 20 years of facility engineering experience with international Pharmaceutical companies, formerly working with Apotex Inc.1, Canada’s largest generic drug manufacturer2. Brian now specializes in technical and manufacturing consulting within the pharma, food and cannabis industries. Brian has decades of experience in full-scale capital expansions and leasehold improvement projects, including leading a green field expansion of a $26M CAD antibiotic production facility, managing the conceptual design to the validation and commencement of commercial operations. Brian has consulted numerous cannabis facilities on EU-GMP regulations and proper facility design, most recently at Northern Green Canada Inc.3. Brian has a degree in engineering and a secondary degree in business management. Brian has also managed many organizational improvement projects to support cost effectiveness, sustainability and process optimization. Brian has previously worked for global companies such as the french multinational firm, Sanofi Pasteur, where he managed a $45 million expansion of the Pertussis vaccine production facility.4 Brain currently leads Glow’s technical build-out and manages its full-scale capital expansions and leasehold improvement projects. Brian primarily focuses on process optimization, cost effectiveness and sustainability for Glow’s manufacturing, facilities and operations.

Glow Appoints Josh Bald as Dedicated CFO

Josh Bald, CPA
CFO

Josh has held senior accounting positions at Ernst and Young5, in the audit assurance sector. Prior to his leadership roles at EY, he obtained an Honours Business Administration degree from Richard Ivey School of Business at Western University, and further to that obtained his Chartered Professional Accountant designation. Josh has international public company and capital markets experience having worked with multiple issuers, and leading financial strategy, growth and corporate compliance which will be a key addition to Glow.

Chris Hopkins has been the CFO of Glow from its inception in 2018, and the Company gives thanks to Chris as a crucial person in the efforts to advance Glow in early stages and oversee its public listing. Chris will continue to advise the Company on strategic initiatives.

Glow LifeTech Management and Directors

W. Clark Kent
CEO & Director

Mr. Kent is a capital markets professional with extensive experience leading corporate development and finance initiatives in the natural resources, technology and life science sectors. For over a decade he has advised emerging companies on strategic planning, finance and recruitment in the North American and international marketplace.

Tom Glawdel, Ph.D
COO

Tom obtained a Ph.D in Mechanical and Mechatronics Engineering from Waterloo in 2012. Mr. Glawdel has 10 years of experience leading high-performing research and development teams in biotechnology and medical technology and is acting Chief Scientific Officer for Relay Medical. He has in-depth knowledge in medical diagnostic development, microfluidics, nanomaterials and a broad experience in building early stage technologies. Previously, he was the director of Product Development and Engineering for a start-up medical device company, 3RCardio, and was Assistant Director of R&D for Xagenic managing cross-functional teams developing a cutting edge molecular diagnostic product. Mr. Glawdel has extensive experience working in a regulated environment developing products requiring Health Canada and FDA approval processes. Tom provides a wide range of valuable skills to Glow and currently leads the operations and technical development projects within the Company.

Rob Carducci
CCO & Director

Mr. Carducci formerly worked at Nestle6 and Kraft Foods7, leading several global brands and their commercial strategy. Most recently Rob served as Marketing Director for the largest cannabis information website in the world, Leafly.com8, which sees roughly 120 million annual website visitors9. Mr. Carducci graduated with an HBA at Ivey Business School in 2009 and is a seasoned marketing executive with over a decade of leadership experience building iconic global brands including Delissio, Drumstick, Smarties and KitKat. As CCO, Roberto is responsible for building Glow’s commercialization strategy and infrastructure to drive market adoption for its technology and product portfolio across North America. Robert provides strategic leadership for defining the commercial path to growth and profitability, and leads the Company’s marketing, sales & business development strategy.

Chris Irwin
Board Member

Chris practices securities and corporate law and has been the President of Irwin Professional Corporation since August, 2006. He advises a number of public companies on a variety of issues including continuous disclosure and regulatory issues, reverse-takeover transactions, initial public offerings and takeover bids. Mr. Irwin also advises boards of directors, including independent committees. Mr. Irwin is a director and/or officer of several public companies and has served as a member of the independent committees for both Trelawney Mining and Exploration Inc. and Seafield Resources. Mr. Irwin obtained an LL.M. from Osgoode Hall Law School in 2009, a LL.B. from the University of New Brunswick in 1994 and a B.A. from Bishop’s University in 1990.

Greg Falck
Board Member

Greg has a diverse leadership background within both the military and private sector. He served nine years as an Electrical and Mechanical Engineering Officer in the Canadian Armed Forces, including two years as a platoon commander in the Canadian Special Operations Regiment responsible for support of the unit’s equipment during all foreign and domestic activities. He also led the development and procurement of a variety of leading-edge military equipment alongside special forces operators, technicians, and industry experts. As head of research and development at Aluula Composites Ltd, Greg and his multidisciplinary team of chemists, engineers, and technologists developed a novel lightweight and ultra high strength composite polymer fabric for commercialization. Their first composite fabric on the market won the ISPO Textrends 2020 Best Product award. Greg graduated from the University of Western Ontario with a Bachelor of Engineering Science in 2009.

Medhanie Tekeste
Board Member

Mr. Tekeste is currently the CIO of Apotex10, Canada’s largest generic drug manufacturer. Medhanie has over 20 years of information systems experience including many years of broad based management expertise in systems development, implementation and support. He is experienced in strategically and cost-effectively utilizing technology to achieve corporate goals. He has extensive global experience in service delivery in the pharmaceutical industry including Quality, Manufacturing and R&D processes. Medhanie also has considerable experience in laboratory quality assurance testing and computer systems validation. Mr. Tekeste graduated from the University of Toronto with a Bachelor of Science degree in Biochemistry in 1987. Later he graduated Pharmaceutical Technology at Seneca College 1998. Lastly, he obtained a diploma in Information Technology from DeVry Technology Institute in 1994. Medhanie advises and oversees key strategic growth opportunities at Glow, and will continue to be a key asset to the Company.

James Van Staveren
Corporate Development

Mr. Van Staveren graduated from Western University in 2014 and has several years of experience in marketing and corporate finance in public company environments. James manages investor relations and supports corporate development initiatives for Glow.

For the full bio’s of management, please visit the company’s website: www.glowlifetech.com

The Company announces that it has granted an aggregate of 500,000 options to purchase Common Shares of the Company at $0.25 and expiring five years from the date of grant, to certain officers, directors and consultants of the Company.

SUBSCRIBE: For more information on Glow or to subscribe to the Company’s mail list visit: https://www.glowlifetech.com/news

About Glow LifeTech Corp.
Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates that unlock the full healing potential of the valuable compounds.

Website: www.glowlifetech.com

Contact:
James Van Staveren
Glow LifeTech Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
ir@glowlifetech.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which filings are available at www.sedar.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
4Front Ventures Corp. Announces Updates to Leadership Team https://mjshareholders.com/4front-ventures-corp-announces-updates-to-leadership-team/ Fri, 30 Jul 2021 19:14:47 +0000 https://www.cannabisfn.com/?p=2927859

Ryan Allway

July 30th, 2021


PHOENIXJuly 30, 2021 /PRNewswire/ – 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”), a vertically integrated, multi-state cannabis operator and retailer, announced the planned stepping down of 4Front Co-Founder and President of Mission Dispensaries Kris Krane, effective immediately, after nearly 11 years of distinguished service with the Company.

The transition of Mr. Krane’s responsibilities in his capacity as president of Mission Dispensaries has been underway for months, and he will continue to serve as a strategic advisor to the Company. 4Front has no immediate plans to fill the president of Mission Dispensaries position and will seek to fill the vacated role at the appropriate time.

4Front’s Chief Executive Officer Leo Gontmakher commented, “Kris has been an invaluable leader not only at our Company and in its formation, success and development, but also in our collective efforts to advance the cannabis industry, the legalization movement and sound regulatory policies. As a frequent speaker at cannabis industry conferences and events around the world, Kris’ work to reform our nation’s misguided drug and marijuana laws, first as the associate director of the National Organization for the Reform of Marijuana Laws (NORML), and then as executive director of Students for Sensible Drug Policy, have helped shape the future of the sector and drug policy reforms for the better. We are grateful for his invaluable contributions to our Company, look forward to working with him in his strategic advisory role, and wish him the best of luck in his future endeavors.”

“In the last 11 years, we went from a few people in a room with an idea, to building a national, vertically integrated cannabis operator with operations and facilities in strategic medical and adult-use cannabis markets including CaliforniaIllinoisMassachusettsMichigan and Washington,” said Kris Krane, 4Front Co-Founder and Strategic Advisor. “I feel incredibly fortunate to have played an instrumental role in 4Front’s journey to become the premier provider of value-driven, quality cannabis products. More than a decade later, the Company has built a strong reputation for high standards and low-cost cultivation and production methodologies earned through a track record of success in facility design, cultivation, genetics, manufacturing, distribution and retail operations. Most importantly, I am proud of the way we have conducted our business, always staying conscious of the role we play in the broader movement to end cannabis prohibition.”

For more information, visit https://4frontventures.com/ and https://missiondispensaries.com/.

About 4Front Ventures Corp.
4Front Ventures Corp. (“4Front” or the “Company”) (CSE: FFNT) (OTCQX: FFNTF) is a national, vertically integrated multi-state cannabis operator with operations and facilities in strategic medical and adult-use cannabis markets, including CaliforniaIllinoisMassachusettsMichigan and Washington. Since its founding in 2011, 4Front has built a strong reputation for its high standards and low-cost cultivation and production methodologies earned through a track record of success in facility design, cultivation, genetics, growing processes, manufacturing, purchasing, distribution, and retail. To date, 4Front has successfully brought to market more than 20 different cannabis brands and nearly 2,000 unique product lines, which are strategically distributed through its fully owned and operated Mission dispensaries and retail outlets in its core markets. As the Company continues to drive value for its shareholders, its team is applying its decade of expertise in the sector across the cannabis industry value chain and ecosystem. For more information, visit https://4frontventures.com/.

Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in 4Front Ventures’ periodic filings with securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements related to future developments and the business and operations of 4Front Ventures, statements regarding when or if transactions will close or if/when required conditions to closing are attained, the impact of the transactions on the business of 4Front and other statements regarding future developments of the business. Although 4Front Ventures has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on satisfying closing conditions, [obtaining regulatory approvals]; and engagement in activities currently considered illegal under U.S. federal laws; change in laws; limited operating history; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. 4Front Ventures disclaims any intention or obligation to update or revise such information, except as required by applicable law, and 4Front Ventures does not assume any liability for disclosure relating to any other company mentioned herein.

SOURCE 4Front

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio https://mjshareholders.com/clearmind-announces-changes-to-senior-management-as-it-accelerates-development-of-its-ip-portfolio/ Wed, 14 Jul 2021 21:43:50 +0000 https://www.cannabisfn.com/?p=2926146

Ryan Allway

July 14th, 2021

Psychedelics


Industry Veteran Dr. Adi Zuloff-Shani Takes The Helm As CEO

Toronto, Ontario–(Newsfile Corp. – July 14, 2021) –  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce changes to its executive management team in conjunction with an accelerated effort to execute the strategic shift to psychedelic drug development as defined in its May 25th Change of Business listing on the Canadian Stock Exchange.

Dr. Adi Zuloff-Shani, PhD., a biomedical research and development executive with over 20 years of strategic and operational leadership in the healthcare industry, has been appointed as Chief Executive Officer. Dr. Zuloff-Shani has extensive experience successfully navigating the highly regulated process of taking therapeutics from discovery to commercialization.

Oz Locker, a proven entrepreneur with significant managerial and operational experience, has been appointed Chief Operating Officer. Mr. Locker most recently served as the CEO of a fully integrated CBD company in the U.S, and prior, he served in several leadership positions in fast growing technological startups. Oz is a veteran Air-Force pilot and has earned his MBA from Harvard Business School.

Gadi Levin, a Qualified Chartered Accountant with over 25 years’ experience in senior financial positions, will become the Company’s Chief Financial Officer. Mr. Levin has served as CFO of several North American publicly listed companies as well as Vice President of Finance and CFO for two Israeli investment houses focused on private equity, hedge funds and real estate and regularly consults with start-up and earlier stage companies.

Ezekiel Golan, inventor of the technology underlying the Company’s Binge Behavior Regulators, will now serve only as a Special Advisor for Innovation and New Initiatives.

“I’m excited to see the technology I created continue to evolve into what will hopefully become proven therapies. Clearmind’s first candidate, a treatment for Alcohol Use Disorder, is expected to treat millions of people who have difficulties managing alcohol consumption” Golan commented.

Golan went on, “As the Company embarks on the rigorous regulatory approval process, it’s critical that they have an experienced management team at the helm. I will continue to support Clearmind as Special Advisor for Innovation and New Initiatives. This is a truer representation of my role at the Company and gives me the liberty to more broadly investigate the many indications for psychedelics as medicine.”

Dr. Zuloff-Shani commented on the appointments, “I believe that psychedelic-based medicine has the potential to revolutionize the way we treat mental health issues, and that Clearmind is positioned to become a leader in the field. We have assembled a management team with the expertise and passion necessary to achieve that objective, and we are all eager to get started.”

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic therapeutics to solve widespread and under-served health problems including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods and supplements.

The Company’s intellectual portfolio currently consists of two patent families. “Binge behavior regulators” has been granted in the U.S., Europe, China, and India, with pending divisional applications in Europe and the US. “Alcohol Beverage Substitutes” has been approved for a European patent, with pending applications in the US, China, and India. We will seek additional patents for our compounds whenever warranted and remain opportunistic with regard to the acquisition of additional IP to build our portfolio.

For further information, please contact:

Investor Relations,
Email: [email protected]
Telephone: (778) 400-5347

General Inquiries,
[email protected]
www.Clearmindmedicine.com

FORWARD-LOOKING STATEMENTS:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing into early stage companies inherently carries a high degree of risk and investment into securities of the Company shall be considered highly speculative.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to U.S. newswire services or dissemination in the United States.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
AgraFlora Appoints Fiona Fitzmaurice as its New Chief Financial Officer https://mjshareholders.com/agraflora-appoints-fiona-fitzmaurice-as-its-new-chief-financial-officer/ Wed, 05 May 2021 16:27:29 +0000 https://www.cannabisfn.com/?p=2919860

Ryan Allway

May 5th, 2021


Former CFO Amicably Departing the Company to Facilitate the Transition

VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce that Fiona Fitzmaurice has been appointed as AgraFlora’s new Chief Financial Officer (“CFO”) effective May 1, 2021, subject to the final acceptance of the Canadian Securities Exchange (the “CSE”). Ms. Fitzmaurice is a Chartered Professional Accountant with over 14 years of experience in accounting and financial control, serving both private companies and public issuers throughout her career. AgraFlora’s former CFO, Peter Nguyen, has amicably agreed to depart the Company in order to facilitate Ms. Fitzmaurice’s transition as the new steward of AgraFlora’s finances.

“On behalf of the Board of Directors, I am pleased to welcome Fiona to AgraFlora’s management team as we continue to evolve the Company’s streamlined corporate strategy and execute on our near-term goal of generating revenues from our core assets,” said Elise Coppens, CEO of AgraFlora. “I would like to thank Peter for his contributions to the Company and his assistance with respect to my own onboarding process, and I appreciate his professionalism during this time of transition,” added Ms. Coppens.

Ms. Fitzmaurice has previously been appointed as CFO of companies that include but are not limited to MacDonald Mines Exploration Ltd., Pasofino Gold and Mojave Jane Brands. Accordingly, Fiona has extensive experience with corporate audits, prospectus filings, private placements, financings and corporate acquisitions. As the foundation of her knowledge base, Ms. Fitzmaurice holds a bachelors’ degree in accounting and finance from Athlone Institute of Technology in Athlone, Ireland.

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a cannabis company building shareholder value through the development of revenue-generating, operated assets in the global cannabis industry. AgraFlora is focused primarily on the Canadian cannabis industry – the world’s most advanced and regulated legal cannabis market. Its flagship Canadian asset is Propagation Services Canada, a large-scale commercial greenhouse in Delta, BC focused on reshaping the Canadian flower market with high-potency, low-cost cannabis. In addition, AgraFlora’s wholly-owned subsidiary, Farmako GmbH, is focused on becoming Europe’s leading distributor of medical cannabis. Farmako currently has active distribution operations in Germany and expects to commence active operations in the United Kingdom in 2021. For more information about AgraFlora, please visit agraflora.ca and its profile page on SEDAR at www.sedar.com.

ON BEHALF OF THE BOARD OF DIRECTORS
Nick Kuzyk, Investor Relations
E: [email protected]
T: (800) 783-6056

For French inquiries:
Maricom Inc.
Remy Scalabrini
E: [email protected]
T: (888) 585-MARI

The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.

Forward-looking Information Cautionary Statement
Except for statements of historic fact this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan” “expect” “project” “intend” “believe” “anticipate” “estimate” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including but not limited to delays or uncertainties with regulatory approvals including that of the CSE. There are uncertainties inherent in forward-looking information including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators which are available at www.sedar.com.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>